Metronomic Capecitabine Plus AI as Initial Therapy in Patients With HR+/HER2- mBC: MECCA Trial
PFS➡️20.9 vs 11.9 mo
📌In regions where access to CDK4/6 inhibitors is limited, this could be an alternative option
(The study was initiated in 2017, at which time palbociclib had already been approved by the FDA, but it likely had not yet been approved in China)
https://t.co/s4FbEAus7H
Hi @TwitterSupport the account for @OncoAlert 🚨has been locked because we updated the birthday to reflect the start of the network March 25, 2019
In doing so our @TwitterBlue verified account was locked out due to AGE restrictions
We're an Oncology⚕️Network
⚠️PLEASE RETWEET‼️
Un Placer apresentar a você a @OncoReporte 🚨
Same Great Content & faculty from @OncoAlert
Pero en Español🇪🇸e portugues🇵🇹
Somos OncoAlert🚨con un poco de Portuñol😉
Saludos,
@weoncologists
Estimados Colegas,
El resumen semanal de @OncoAlert 🚨y @ecancer@ecancer_espanol ya esta disponible!
Lo mejor en Oncologia durante la semana
Agosto 8-14, 2022
Saludos,
@weoncologists & @leitooo_vr